Galanin expression within the basal forebrain in Alzheimer's disease: Comments on therapeutic potential

Elliott J. Mufson, Ulrika Kahl, Robert Bowser, Deborah C Mash, Jeffrey H. Kordower, Darlene C. Deecher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.

Original languageEnglish
Pages (from-to)291-304
Number of pages14
JournalAnnals of the New York Academy of Sciences
Volume863
DOIs
StatePublished - Dec 1 1998

Fingerprint

Galanin
Cholinergic Agents
Alzheimer Disease
Galanin Receptors
Neurons
Therapeutics
Acetylcholine
Septal Nuclei
Entorhinal Cortex
Basal Forebrain
Neuron
Alzheimer's Disease
Hominidae
Neurology
Interneurons
Amygdala
Neuropeptides
Cognition
Primates
Haplorhini

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Galanin expression within the basal forebrain in Alzheimer's disease : Comments on therapeutic potential. / Mufson, Elliott J.; Kahl, Ulrika; Bowser, Robert; Mash, Deborah C; Kordower, Jeffrey H.; Deecher, Darlene C.

In: Annals of the New York Academy of Sciences, Vol. 863, 01.12.1998, p. 291-304.

Research output: Contribution to journalArticle

Mufson, Elliott J. ; Kahl, Ulrika ; Bowser, Robert ; Mash, Deborah C ; Kordower, Jeffrey H. ; Deecher, Darlene C. / Galanin expression within the basal forebrain in Alzheimer's disease : Comments on therapeutic potential. In: Annals of the New York Academy of Sciences. 1998 ; Vol. 863. pp. 291-304.
@article{d46facae5e4742e7876ed5992487ffaa,
title = "Galanin expression within the basal forebrain in Alzheimer's disease: Comments on therapeutic potential",
abstract = "The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.",
author = "Mufson, {Elliott J.} and Ulrika Kahl and Robert Bowser and Mash, {Deborah C} and Kordower, {Jeffrey H.} and Deecher, {Darlene C.}",
year = "1998",
month = "12",
day = "1",
doi = "10.1111/j.1749-6632.1998.tb10703.x",
language = "English",
volume = "863",
pages = "291--304",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Galanin expression within the basal forebrain in Alzheimer's disease

T2 - Comments on therapeutic potential

AU - Mufson, Elliott J.

AU - Kahl, Ulrika

AU - Bowser, Robert

AU - Mash, Deborah C

AU - Kordower, Jeffrey H.

AU - Deecher, Darlene C.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.

AB - The inhibitory neuropeptide galanin has widespread distribution throughout the central nervous system. Studies indicate that galanin modulates cognition by regulating cholinergic basal forebrain (CBF) neuron function. The chemoanatomic organization of galanin within the mammalian CBF differs across species. In monkeys, all CBF neurons coexpress galanin, whereas in apes and humans galanin is found within a separate population of interneurons that are in close apposition to the CBF perikarya. Pharmacologic investigations revealed a low and high affinity galanin receptor within the basal forebrain in humans. In vitro autoradiographic investigations of the primate brain indicate that galanin receptors are concentrated within the anterior subfields of the CBF as well as the bed nucleus of the stria terminalis, amygdala, and entorhinal cortex. Galaninergic fibers hyperinnervate remaining CBF neurons in Alzheimer's disease. Because galanin inhibits the release of acetylcholine in the hippocampus, it has been suggested that the overexpression of galanin in Alzheimer's disease may downregulate the production of acetylcholine within CBF perikarya, further exacerbating cholinergic cellular dysfunction in this disorder. These observations suggest that the development of a potent galanin antagonist would be a useful step towards the successful pharmacologic treatment of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0032430457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032430457&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1998.tb10703.x

DO - 10.1111/j.1749-6632.1998.tb10703.x

M3 - Article

C2 - 9928179

AN - SCOPUS:0032430457

VL - 863

SP - 291

EP - 304

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -